ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

P Schöffski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.